Greenwich LifeSciences, Inc. (GLSI) announced that two abstracts from its Phase III FLAMINGO‑01 trial have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, scheduled for April 17‑22, 2026. The acceptance was disclosed on February 24, 2026, and the abstracts will be published on March 17, 2026, with full presentations slated for April 17, 2026.
One abstract will be the first co‑authored by GLSI and the full FLAMINGO‑01 Steering Committee, underscoring the collaborative nature of the study. The second abstract will be presented as a poster, providing additional visibility into the trial’s early data. Both presentations will highlight progress in evaluating GLSI‑100, the company’s Fast‑Track designated immunotherapy aimed at preventing breast cancer recurrence.
GLSI‑100 combines a GP2 peptide with GM‑CSF to stimulate an immune response against residual HER2‑positive breast cancer cells. The Phase IIb study demonstrated an 80% or greater reduction in metastatic recurrence over five years, a result that exceeds the approximately 50% reduction achieved by existing HER2 therapies. The FLAMINGO‑01 trial is designed to confirm these findings in a larger, global population, and the abstract acceptance signals that the study is on track and that the data are compelling enough for AACR consideration.
The acceptance of these abstracts is a key milestone for GLSI. It validates the scientific strategy behind GLSI‑100, reinforces the company’s Fast‑Track designation, and positions GLSI to attract potential partners and investors. The early visibility into trial progress may accelerate regulatory discussions and support future funding rounds, strengthening GLSI’s trajectory toward a potential approval that could address a significant unmet need in breast cancer care.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.